FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2509099384> ?p ?o ?g. }

• W2509099384 endingPage "1298" @default.
• W2509099384 startingPage "1286" @default.
• W2509099384 abstract "Abstract Purpose: The PI3K–AKT–mTOR signaling pathway is frequently activated in glioblastoma and offers several druggable targets. However, clinical efficacy of PI3K/mTOR inhibitors in glioblastoma has not yet been demonstrated. Insufficient drug delivery may limit the efficacy of PI3K/mTOR inhibitors against glioblastoma. The presence of the efflux transporters ABCB1/Abcb1 (P-glycoprotein, MDR1) and ABCG2/Abcg2 (BCRP) at the blood–brain barrier (BBB) restricts the brain penetration of many drugs. Experimental Design: We used in vitro drug transport assays and performed pharmacokinetic/pharmacodynamic studies in wild-type and ABC-transporter knockout mice. The efficacy of PI3K-mTOR inhibition was established using orthotopic allograft and genetically engineered spontaneous glioblastoma mouse models. Results: The mTOR inhibitors rapamycin and AZD8055 are substrates of ABCB1, whereas the dual PI3K/mTOR inhibitor NVP-BEZ235 and the PI3K inhibitor ZSTK474 are not. Moreover, ABCG2 transports NVP-BEZ235 and AZD8055, but not ZSTK474 or rapamycin. Concordantly, Abcb1a/b−/−;Abcg2−/− mice revealed increased brain penetration of rapamycin (13-fold), AZD8055 (7.7-fold), and NVP-BEZ235 (4.5-fold), but not ZSTK474 relative to WT mice. Importantly, ABC transporters limited rapamycin brain penetration to subtherapeutic levels, while the reduction in NVP-BEZ235 brain penetration did not prevent target inhibition. NVP-BEZ235 and ZSTK474 demonstrated antitumor efficacy with improved survival against U87 orthotopic gliomas, although the effect of ZSTK474 was more pronounced. Finally, ZSTK474 prolonged overall survival in Cre-LoxP conditional transgenic Pten;p16Ink4a/p19Arf;K-Rasv12;LucR mice, mainly by delaying tumor onset. Conclusions: PI3K/mTOR inhibitors with weak affinities for ABC transporters can achieve target inhibition in brain (tumors), but have modest single-agent efficacy and combinations with (BBB penetrable) inhibitors of other activated pathways may be required. Clin Cancer Res; 23(5); 1286–98. ©2016 AACR." @default.
• W2509099384 created "2016-09-16" @default.
• W2509099384 creator A5032011616 @default.
• W2509099384 creator A5034151807 @default.
• W2509099384 creator A5037815807 @default.
• W2509099384 creator A5039593027 @default.
• W2509099384 creator A5040734757 @default.
• W2509099384 creator A5042321762 @default.
• W2509099384 creator A5061723541 @default.
• W2509099384 creator A5062227574 @default.
• W2509099384 creator A5073588166 @default.
• W2509099384 creator A5088035130 @default.
• W2509099384 date "2017-02-28" @default.
• W2509099384 modified "2023-10-16" @default.
• W2509099384 title "PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models" @default.
• W2509099384 cites W1852342230 @default.
• W2509099384 cites W1886326176 @default.
• W2509099384 cites W1944657519 @default.
• W2509099384 cites W1964296201 @default.
• W2509099384 cites W1966720603 @default.
• W2509099384 cites W1977267072 @default.
• W2509099384 cites W1982678312 @default.
• W2509099384 cites W1992477322 @default.
• W2509099384 cites W1993337516 @default.
• W2509099384 cites W1995725988 @default.
• W2509099384 cites W1996102081 @default.
• W2509099384 cites W2011424260 @default.
• W2509099384 cites W2017739035 @default.
• W2509099384 cites W2040827479 @default.
• W2509099384 cites W2054455334 @default.
• W2509099384 cites W2062418261 @default.
• W2509099384 cites W2063909696 @default.
• W2509099384 cites W2072943045 @default.
• W2509099384 cites W2074433596 @default.
• W2509099384 cites W2075883917 @default.
• W2509099384 cites W2079785947 @default.
• W2509099384 cites W2084286417 @default.
• W2509099384 cites W2089413248 @default.
• W2509099384 cites W2094067427 @default.
• W2509099384 cites W2098983401 @default.
• W2509099384 cites W2104076039 @default.
• W2509099384 cites W2104387616 @default.
• W2509099384 cites W2108291133 @default.
• W2509099384 cites W2109816625 @default.
• W2509099384 cites W2110949408 @default.
• W2509099384 cites W2116622644 @default.
• W2509099384 cites W2126783165 @default.
• W2509099384 cites W2128225881 @default.
• W2509099384 cites W2140254135 @default.
• W2509099384 cites W2147775209 @default.
• W2509099384 cites W2155009617 @default.
• W2509099384 cites W2157922236 @default.
• W2509099384 cites W2158305336 @default.
• W2509099384 cites W2163846920 @default.
• W2509099384 cites W2170316270 @default.
• W2509099384 cites W817872913 @default.
• W2509099384 cites W1999404089 @default.
• W2509099384 doi "https://doi.org/10.1158/1078-0432.ccr-16-1276" @default.
• W2509099384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27553832" @default.
• W2509099384 hasPublicationYear "2017" @default.
• W2509099384 type Work @default.
• W2509099384 sameAs 2509099384 @default.
• W2509099384 citedByCount "53" @default.
• W2509099384 countsByYear W25090993842017 @default.
• W2509099384 countsByYear W25090993842018 @default.
• W2509099384 countsByYear W25090993842019 @default.
• W2509099384 countsByYear W25090993842020 @default.
• W2509099384 countsByYear W25090993842021 @default.
• W2509099384 countsByYear W25090993842022 @default.
• W2509099384 countsByYear W25090993842023 @default.
• W2509099384 crossrefType "journal-article" @default.
• W2509099384 hasAuthorship W2509099384A5032011616 @default.
• W2509099384 hasAuthorship W2509099384A5034151807 @default.
• W2509099384 hasAuthorship W2509099384A5037815807 @default.
• W2509099384 hasAuthorship W2509099384A5039593027 @default.
• W2509099384 hasAuthorship W2509099384A5040734757 @default.
• W2509099384 hasAuthorship W2509099384A5042321762 @default.
• W2509099384 hasAuthorship W2509099384A5061723541 @default.
• W2509099384 hasAuthorship W2509099384A5062227574 @default.
• W2509099384 hasAuthorship W2509099384A5073588166 @default.
• W2509099384 hasAuthorship W2509099384A5088035130 @default.
• W2509099384 hasBestOaLocation W25090993841 @default.
• W2509099384 hasConcept C104317684 @default.
• W2509099384 hasConcept C149011108 @default.
• W2509099384 hasConcept C2778227246 @default.
• W2509099384 hasConcept C44312359 @default.
• W2509099384 hasConcept C502942594 @default.
• W2509099384 hasConcept C512196 @default.
• W2509099384 hasConcept C55493867 @default.
• W2509099384 hasConcept C62478195 @default.
• W2509099384 hasConcept C71924100 @default.
• W2509099384 hasConcept C75217442 @default.
• W2509099384 hasConcept C86554907 @default.
• W2509099384 hasConcept C86803240 @default.
• W2509099384 hasConcept C95444343 @default.
• W2509099384 hasConcept C98274493 @default.
• W2509099384 hasConceptScore W2509099384C104317684 @default.
• W2509099384 hasConceptScore W2509099384C149011108 @default.

• next